5:30 PM
 | 
Aug 18, 2014
 |  BC Extra  |  Top Story

NICE upholds Ferring appeal on Firmagon

The U.K.'s NICE will reconsider an April final appraisal determination (FAD) for Firmagon degarelix from Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) after an agency panel upheld an appeal by the company. The FAD recommended Firmagon to treat advanced hormone-dependent prostate cancer only in a subgroup of patients with spinal metastases who present signs or symptoms of spinal cord...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >